Evidence map›Paper›PMID 42614931›Full record

ArticleStem cells international2026

Comprehensive Preclinical Safety Evaluation of Clinical-Grade hESC-Derived Multipotent Mesenchymal Stem Cells for Interstitial Cystitis.

Jeong Min Shin, Ah Reum Kang, Dong Seol Gwak, Su Jin Kim, Jin Won Seo, Eun-Young Kim, Ki-Sung Hong, Se-Pill Park, Hyung-Min Chung

Abstract read
In one paragraph

Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jeong Min ShinDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0009-0001-3686-9432
Ah Reum KangDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0009-0007-3671-1663
Dong Seol GwakDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0009-0004-2088-6395
Su Jin KimDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0009-0002-4545-0016
Jin Won SeoDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0000-0003-1846-3807
Eun-Young KimDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-6299-6876
Ki-Sung HongDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0000-0001-5623-4875
Se-Pill ParkDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0000-0002-6965-7831
Hyung-Min ChungDepartment of Research and Development, Mirae Cell Bio Co. Ltd., Seoul, Republic of Korea.ORCID https://orcid.org/0009-0009-7720-9009

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human embryonic stem cell (hESC)-derived multipotent mesenchymal stem cells (MMSCs) offer therapeutic potential for interstitial cystitis (IC); however, safety concerns, such as tumorigenicity from residual undifferentiated hESCs, must be thoroughly addressed. To address these concerns, we conducted comprehensive in vitro and in vivo safety assessments of clinical-grade MMSCs. Flow cytometry, qRT-PCR, and/or RNA sequencing confirmed the absence of pluripotency markers, including

Indexed as

biodistributionhuman embryonic stem cellsinterstitial cystitismultipotent mesenchymal stem cellstumorigenicity

Identifiers

PMID42614931
PMCPMC13484282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.